Loading...
Guest User
Welcome! Please login.
* - Tentative Dates
The company proposes to utilize the net proceeds from the Issue towards funding the following objects:
Genpharmasec Limited's revenue decreased by -6.56% and profit after tax (PAT) rose by 637.15% between the financial year ending with March 31, 2023 and March 31, 2022.
| Period Ended | 31 Mar 2023 | 31 Mar 2022 | 31 Mar 2021 |
| Assets | 19.88 | 21.65 | 27.82 |
| Revenue | 25.62 | 27.41 | 21.64 |
| Profit After Tax | 1.12 | -0.21 | 1.26 |
| Net Worth | 29.91 | 28.78 | 28.99 |
| Reserves and Surplus | 28.78 | 28.99 | |
| Total Borrowing | 3.08 | ||
| Amount in ₹ Crore | |||
Genpharmasec Limited was founded in 1992 and was initially involved in the manufacture and trading of organic and inorganic chemicals, dyes and pigments. However, since 2018, the company has shifted its focus to the purchase, sale and distribution of various pharmaceutical, medical and drug preparations. The company has also decided to enter the securities market.
The company has entered into a partnership with Abbott Point of Care Corporation INC, based in the USA, to distribute their special diagnostic device called i-STAT 1 Analyzer. This device is used exclusively in intensive care units and hospitals for immediate test results. The i-STAT 1 Analyzer is lightweight, portable and easy to use. It utilises the advanced technology of the i-STAT test cassettes. Together they form the i-STAT system - a point-of-care testing platform that provides healthcare professionals with diagnostic information at the time and place it is needed.
